Description
Rimexolone, an ophthalmic corticosteroid, was launched in 1995 in the U.S.A. for
the treatment of postoperative inflammation following ocular surgery and anterior
uveitis. Rimexolone has high corticoid receptor affinity and is a potent local
antiinflammatory agent with minimal systemic effects and virtually no atrophogenic
action in many animal models studied, unique among a wide range of topical steroids.
Rapid onset, long duration of action plus a superior safety profile are characteristics of
rimexolone. It was also approved in Europe for the treatment of rheumatoid arthritis and
is currently in clinical trials for tendinitis and osteoarthritis.
Originator
Akzo (Netherlands)
Uses
Anti-inflammatory (local).
Definition
ChEBI: Rimexolone is a 20-oxo steroid.
brand name
Vexol (Alcon).
General Description
Rimexolone, 11β-hydroxy-16α,17α-dimethyl-17-(1-oxopropyl)androsta-1,4-diene-3-one,like medrysone and fluorometholone, lacks the C21 OHgroup. In addition, rimexolone has an additional methylgroup in the 17 -position, a site where an OH group is typicallyfound. Rimexolone is available as a suspension forophthalmic use.
